Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies
Ramona Vladea, Remo Panaccione, W. Rachel Duan, Marc Ferrante et al.
Citations
10 citations
Journal
Journal of Crohn s and Colitis
Topics
Inflammatory Bowel Disease
Field-Weighted Citation Impact (FWCI)
18.17
article
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies
Ramona Vladea, Remo Panaccione, W. Rachel Duan, Marc Ferrante, Laurent Peyrin‐Biroulet, David T. Rubin, Jasmina Kalabic, Pierre Morisset, Geert D’Haens, Édouard Louis, Marla Dubinsky, Karen B. Chien, Patrick Hecht, Su Chen, Yafei Zhang, Ken Takeuchi, Jean–Frédéric Colombel, Ling Cheng, Stefan Schreiber
article en
10 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Crohn s and ColitisVol. 19(1)
Institutions
University of Calgary (CA), Ludwigshafen University of Business and Society (DE), McGill University Health Centre (CA), AbbVie (United States) (US), Christian-Albrechts-Universität zu Kiel (DE), University of Chicago (US), Centre Hospitalier Régional et Universitaire de Nancy (FR), Centre d’Investigation Clinique Innovation Technologique de Nancy (FR), University Hospital Schleswig-Holstein (DE), AbbVie (Germany) (DE), Klinikum Ludwigshafen (DE), Centre Hospitalier Universitaire de Liège (BE), Clinique Hartmann (FR), Amsterdam University Medical Centers (NL), Kashiwa Municipal Hospital (JP), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), University of Amsterdam (NL), University of Lübeck (DE), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)